CA2340757A1 - Administration d'antioxydants liposomaux encapsules et leurs applications - Google Patents

Administration d'antioxydants liposomaux encapsules et leurs applications Download PDF

Info

Publication number
CA2340757A1
CA2340757A1 CA002340757A CA2340757A CA2340757A1 CA 2340757 A1 CA2340757 A1 CA 2340757A1 CA 002340757 A CA002340757 A CA 002340757A CA 2340757 A CA2340757 A CA 2340757A CA 2340757 A1 CA2340757 A1 CA 2340757A1
Authority
CA
Canada
Prior art keywords
composition
liposomal
antioxidant
hydrophilic
nac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002340757A
Other languages
English (en)
Inventor
Pang N. Shek
Zacharias E. Suntres
Jie Fan
Ori D. Rotstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minister of National Defence of Canada
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2340757A1 publication Critical patent/CA2340757A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une composition liposomale, un agent sulfhydryle hydrophile et un antioxydant lipophile, à savoir la N-acétyl cystéine et/ou .alpha.-tocophérol, ainsi qu'un procédé d'administration par mise en contact de la composition liposomale avec un tissu pulmonaire de mammifère permettant d'obtenir un effet antioxydant prolongé.
CA002340757A 1999-07-07 2000-07-07 Administration d'antioxydants liposomaux encapsules et leurs applications Abandoned CA2340757A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14254599P 1999-07-07 1999-07-07
US60/142,545 1999-07-07
PCT/CA2000/000806 WO2001003669A2 (fr) 1999-07-07 2000-07-07 Administration d'antioxydants liposomaux encapsules et leurs applications

Publications (1)

Publication Number Publication Date
CA2340757A1 true CA2340757A1 (fr) 2001-01-18

Family

ID=22500256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340757A Abandoned CA2340757A1 (fr) 1999-07-07 2000-07-07 Administration d'antioxydants liposomaux encapsules et leurs applications

Country Status (5)

Country Link
EP (1) EP1133278A2 (fr)
JP (1) JP2003504322A (fr)
AU (1) AU6142700A (fr)
CA (1) CA2340757A1 (fr)
WO (1) WO2001003669A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
US20100098752A1 (en) * 2007-01-18 2010-04-22 Pinsky Mark A Materials and Methods for Delivering Antioxidants into the Skin
AU2008345068A1 (en) 2007-12-26 2009-07-09 Mark A. Pinsky Collagen formulations for improved skin care
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
RU2011142620A (ru) * 2009-03-25 2013-04-27 Новартис Аг ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЛЕКАРСТВЕННОЕ СРЕДСТВО И киРНК
CN101829075B (zh) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
US12036321B2 (en) 2020-04-03 2024-07-16 Vivacelle Bio, Inc. Compositions and methods for treating or preventing multiple organ dysfunction syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress

Also Published As

Publication number Publication date
AU6142700A (en) 2001-01-30
EP1133278A2 (fr) 2001-09-19
JP2003504322A (ja) 2003-02-04
WO2001003669A2 (fr) 2001-01-18
WO2001003669A3 (fr) 2001-07-12

Similar Documents

Publication Publication Date Title
US4877619A (en) Liposomal vesicles for intraperitoneal administration of therapeutic agents
EP0632719B1 (fr) Methode de traitement de tissus infectes
US6593294B1 (en) Pharmaceutical composition comprising Factor VIII and neutral liposomes
EP0591492B1 (fr) Composition pharmaceutique contenant un systeme defini de lipides
JP3571335B2 (ja) リポゾームマイクロレシーバー組成物および方法
AU740111B2 (en) Hyaluronic drug delivery system
JP4598908B2 (ja) カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体
EP0692961A1 (fr) Procede de production de liposomes
OA12799A (en) Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease.
US20070003607A1 (en) Neutral liposome-encapsulated compounds and methods of making and using thereof
CA2340757A1 (fr) Administration d'antioxydants liposomaux encapsules et leurs applications
Suntres et al. Liposomal α-tocopherol alleviates the progression of paraquat-induced lung damage
Ogata Characteristics and function of human hemoglobin vesicles as an oxygen carrier
US20120207821A1 (en) Liposomal formulation and use thereof
JPH08508504A (ja) 抗酸化剤アルキルアリール・ポリエーテルアルコール・ポリマー類
Goins et al. Inclusion of ganglioside GM1 into liposome encapsulated hemoglobin does not extend circulation persistence at clinically relevant doses
JPH075477B2 (ja) ヘモグロビン含有リポソームおよびその製法
JPH069374A (ja) リポソ−ム製剤およびその製造法
Schwinke et al. Effect of entrapped markers on the in situ jejunal uptake from liposomal systems
AU776014B2 (en) Use of complexes among cationic liposomes and polydeoxyribonucleotides as medicaments
JPH08502060A (ja) 血餅−溶解タンパク質の部位−特異的放出用医薬組成物
IL130405A (en) Use of complexes between cationic liposomes and polydeoxyribonucleotides for preparation of medicaments
IL139053A (en) Pharmaceutical composition comprising factor VIII and neutral colloidal particles

Legal Events

Date Code Title Description
FZDE Dead